Veradermics insider sells 750K shares at $107

Veradermics, Inc (MANE) had multiple entities associated with the reporting group, including Montanova Capital, LLC and Averill funds, report transactions in its securities.

Rhea-AI Filing Summary

Veradermics, Inc (MANE) had multiple entities associated with the reporting group, including Montanova Capital, LLC and Averill funds, report transactions in its securities. On 2026-08-20 they exercised 300,000 Pre-Funded Warrants into 300,000 shares of common stock, all reported as indirect ownership. On 2026-08-19 they reported indirect open-market or private sales of an aggregate 750,000 shares of common stock at a reported price of $107.25 per share. Resulting ownership balances are not provided in the data shown.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 6 txns

Insider MONTANOVA CAPITAL, LLC, Cowen Aaron, Averill Master Fund, Ltd., Averill Madison Master Fund, Ltd.

Role Director | Insider | Director | Director

Sold 750,000 shs ($80.44M)

Approx. gross sale proceeds $80.44M

Type	Security	Shares	Price	Value
In-the-Money Exercise	Pre-Funded Warrants F6, F4, F7, F8, F1	149,000	$0.00	$0.00
In-the-Money Exercise	Pre-Funded Warrants F6, F5, F7, F8, F1	151,000	$0.00	$0.00
In-the-Money Exercise	Common stock, par value $0.00001 per share F4, F6, F1	149,000	--	--
In-the-Money Exercise	Common stock, par value $0.00001 per share F5, F6, F1	151,000	--	--
Sale	Common stock, par value $0.00001 per share F2, F1	690,601	$107.25	$74.07M
Sale	Common stock, par value $0.00001 per share F3, F1	59,399	$107.25	$6.37M

Holdings After Transaction: Pre-Funded Warrants — 0 contracts (Indirect, See footnotes); Common stock, par value $0.00001 per share — 612,033 shares (Indirect, See footnotes)

Footnotes (8)

1. F1. Notes are included on Exhibit 99.1.
2. F2. Notes are included on Exhibit 99.1.
3. F3. Notes are included on Exhibit 99.1.
4. F4. Notes are included on Exhibit 99.1.
5. F5. Notes are included on Exhibit 99.1.
6. F6. Notes are included on Exhibit 99.1.
7. F7. Notes are included on Exhibit 99.1.
8. F8. Notes are included on Exhibit 99.1.

Key Figures

Pre-Funded Warrants exercised: 300,000 warrants Common shares received on exercise: 300,000 shares Common shares sold: 750,000 shares +3 more

6 metrics

Pre-Funded Warrants exercised 300,000 warrants Exercised into common stock on 2026-08-20 via two X-code transactions

Common shares received on exercise 300,000 shares Common stock obtained from exercising Pre-Funded Warrants on 2026-08-20

Common shares sold 750,000 shares Indirect sales reported on 2026-08-19 in two S-code transactions

Sale price per share $107.25 per share Price for the 690,601- and 59,399-share sales on 2026-08-19

Net buy/sell shares 750,000 shares net-sell Reported in transaction summary as net-sell across all transactions

Exercise transactions count 2 exercises Two X-code derivative exercises of Pre-Funded Warrants

Key Terms

Pre-Funded Warrants, indirect ownership, Exercise of in-the-money or at-the-money derivative security

3 terms

Pre-Funded Warrants financial

"security_title: "Pre-Funded Warrants""

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

indirect ownership financial

"direct_or_indirect: "I" and nature_of_ownership: "See footnotes""

Exercise of in-the-money or at-the-money derivative security financial

"transaction_code_description: "Exercise of in-the-money or at-the-money""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions were reported for Veradermics, Inc (MANE)?

Reporting entities associated with Veradermics, Inc disclosed exercises of 300,000 Pre-Funded Warrants into common stock on 2026-08-20 and indirect sales of an aggregate 750,000 common shares on 2026-08-19 at $107.25 per share.

How many Veradermics (MANE) Pre-Funded Warrants were exercised?

On 2026-08-20, reporting entities exercised a total of 300,000 Pre-Funded Warrants, receiving 300,000 shares of Veradermics common stock. These exercises were reported with transaction code X as exercises of in-the-money or at-the-money derivative securities.

How many Veradermics (MANE) shares were sold and at what price?

On 2026-08-19, reporting entities disclosed indirect sales totaling 750,000 shares of Veradermics common stock at a reported price of $107.25 per share, using transaction code S for sales in open market or private transactions.

Were the Veradermics (MANE) insider transactions direct or indirect holdings?

All reported transactions were classified as indirect ownership, with the nature of ownership referring to footnotes and involving entities such as Montanova Capital, LLC and Averill funds rather than direct personal holdings.

Were Veradermics (MANE) insider trades made under a Rule 10b5-1 plan?

The Rule 10b5-1 checkbox was not checked for these transactions, and the available footnotes simply state that additional notes are in Exhibit 99.1, so there is no indication here that these trades were executed under a Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/21/2026 - 06:12 PM EDT Accepted by SEC EDGAR 08/21/2026 - 06:11 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MONTANOVA CAPITAL, LLC

(Last) (First) (Middle)

11 E 26TH STREET

16TH FLOOR

(Street)

NEW YORK NEW YORK 10010

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Veradermics, Inc [ MANE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common stock, par value $0.00001 per share	08/19/2026		S		690,601(2)	D	$107.25	2,957,937	I(1)	See footnotes(1)(2)
Common stock, par value $0.00001 per share	08/19/2026		S		59,399(3)	D	$107.25	461,033	I(1)	See footnotes(1)(3)
Common stock, par value $0.00001 per share	08/20/2026		X		149,000(4)	A	(6)	3,106,937	I(1)	See footnotes(1)(4)
Common stock, par value $0.00001 per share	08/20/2026		X		151,000(5)	A	(6)	612,033	I(1)	See footnotes(1)(5)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Pre-Funded Warrants	(6)	08/20/2026		X			149,000(4)	(7)(8)	(7)	Common Stock	149,000(7)	$0	0	I(1)	See footnotes(1)(4)
Pre-Funded Warrants	(6)	08/20/2026		X			151,000(5)	(7)(8)	(7)	Common Stock	151,000(7)	$0	0	I(1)	See footnotes(1)(5)

1. Name and Address of Reporting Person^*

MONTANOVA CAPITAL, LLC

(Last) (First) (Middle)

11 E 26TH STREET

16TH FLOOR

(Street)

NEW YORK NEW YORK 10010

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Cowen Aaron

(Last) (First) (Middle)

C/O MONTANOVA CAPITAL, LLC

11 E 26TH, 16TH FLOOR

(Street)

NEW YORK NEW YORK 10010

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			See footnotes

1. Name and Address of Reporting Person^*

Averill Master Fund, Ltd.

(Last) (First) (Middle)

C/O MONTANOVA CAPITAL, LLC

11 E 26TH, 16TH FLOOR

(Street)

NEW YORK NEW YORK 10010

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Averill Madison Master Fund, Ltd.

(Last) (First) (Middle)

C/O MONTANOVA CAPITAL, LLC

11 E 26TH, 16TH FLOOR

(Street)

NEW YORK NEW YORK 10010

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

Explanation of Responses:

1. Notes are included on Exhibit 99.1.

2. Notes are included on Exhibit 99.1.

3. Notes are included on Exhibit 99.1.

4. Notes are included on Exhibit 99.1.

5. Notes are included on Exhibit 99.1.

6. Notes are included on Exhibit 99.1.

7. Notes are included on Exhibit 99.1.

8. Notes are included on Exhibit 99.1.

Remarks:

Exhibit List: Exhibit 99.1 - Explanation of Responses Exhibit 99.2 - Joint Filer Information Exhibit 99.3 - Joint Filers' Signature

	Montanova Capital, LLC; By: /s/ Andrew Nathanson, General Counsel & Chief Compliance Officer	08/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)